Akebia Therapeutics (AKBA) Ownership - Who owns Akebia Therapeutics?

Key Takeaways

• AKBA is the Nasdaq ticker for Akebia Therapeutics, Inc., a biopharmaceutical company focused on treating kidney disease.
• The company markets two U.S. FDA-approved products: Vafseo (vadadustat) and Auryxia (ferric citrate).
• Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia became a public company in 2014.
• Its business model centers on commercializing its own kidney-disease therapies while advancing a clinical pipeline of mid- and early-stage drug candidates.
• Akebia faces generic competition for Auryxia, which lost U.S. market exclusivity in March 2025, making Vafseo a key growth driver.

Introduction

Akebia Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company dedicated to improving the lives of people impacted by kidney disease. Investors follow AKBA because the company represents a relatively rare example of a smaller biotech that has moved from research and development into the direct commercialization of its own approved medicines, rather than relying solely on larger partners to bring products to market.

Company Overview and History

Akebia Therapeutics was founded in 2007 and is incorporated in the State of Delaware. The company is headquartered in Cambridge, Massachusetts, a hub for biotechnology innovation, and became publicly traded in 2014 on the Nasdaq under the ticker AKBA. In December 2018, Akebia completed a merger with Keryx Biopharmaceuticals, a transaction that brought the commercial product Auryxia into Akebia's portfolio and strengthened its presence in the kidney-disease market.

Business Model and Core Products

Akebia operates as a single reporting segment focused on developing and commercializing therapeutics for kidney disease. Its revenue comes primarily from product sales in the United States, supplemented by license, royalty, and supply arrangements with collaboration partners in markets such as Japan, Europe, Australia, South Korea, and Taiwan.

Akebia's commercial portfolio is built around two approved medicines:

• Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It was approved by the U.S. Food and Drug Administration (FDA) in March 2024 for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least three months, and was launched commercially in the United States in early 2025.
• Auryxia (ferric citrate) is approved for controlling serum phosphorus levels in adult patients with dialysis-dependent CKD and for treating iron deficiency anemia in adults with non-dialysis-dependent CKD. Auryxia lost U.S. market exclusivity in March 2025, exposing it to generic competition.

Beyond its marketed products, Akebia maintains a pipeline of clinical-stage candidates targeting rare kidney diseases, including praliciguat (an oral soluble guanylate cyclase activator in development for focal segmental glomerulosclerosis, or FSGS), AKB-097 (a complement inhibitor), and AKB-9090 (an early-stage HIF-PH inhibitor).

Market Position and Revenue Sources

Akebia's financial profile is anchored by product revenue. For the full year 2025, the company reported total revenue of approximately $236 million, with net product revenue of roughly $227 million. Vafseo contributed about $45.8 million in its first full year of U.S. sales, while Auryxia generated approximately $181.5 million, including sales of an authorized generic version following the loss of exclusivity.

The company's market position is shaped by the concentrated nature of the dialysis industry, where a small number of large dialysis organizations influence treatment protocols. Akebia's commercial strategy relies on securing prescribing access and observed-dosing protocols at these organizations to drive adoption of Vafseo as a potential standard of care for anemia management in dialysis patients.

Why Investors Follow AKBA

Investors track AKBA for several long-term reasons. First, Vafseo's U.S. launch represents a meaningful commercial growth opportunity in a large anemia market, with the company generating clinical and health-economic data aimed at supporting broader physician adoption. Second, Akebia's pipeline in rare kidney disease offers potential future value beyond its current products. Third, the company's transition toward profitability — with a narrowed net loss and a strengthened cash position in 2025 — signals progress in its evolution from a research-focused biotech into a commercially self-sustaining enterprise.

Risks and Important Considerations

Investing in AKBA carries meaningful risks that investors should understand. Auryxia's loss of exclusivity exposes a significant portion of revenue to generic competition, and additional generic entrants are expected to pressure sales over time. Vafseo's reimbursement is currently supported by a transitional add-on payment that is scheduled to phase out, creating uncertainty about long-term pricing under Medicare's dialysis payment system.

Akebia also operates in a competitive and heavily regulated industry. Adoption of new therapies by nephrologists can be slow, and the company faces competition from established erythropoiesis-stimulating agents (ESAs) as well as from other drug developers. Additionally, Akebia relies on third-party contract manufacturers for its drug supply, and its pipeline remains in relatively early stages, with no guarantee that clinical trials will succeed. As with most biotechnology companies, regulatory decisions, clinical trial outcomes, and reimbursement changes can materially affect its business and financial profile.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to build a watchlist aligned with your approach.

Conclusion

Akebia Therapeutics stands out as a focused, kidney-disease specialist that has successfully transitioned into commercializing its own therapies. With an established product base, an emerging growth driver in Vafseo, and a pipeline aimed at rare kidney conditions, the company remains a notable name for investors interested in the biotechnology and renal-therapeutics space — while also carrying the execution, competition, and reimbursement risks typical of the sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations